Davide Capodanno/LinkedIn
Jan 11, 2026, 03:54
DAPT De-escalation After PCI․ Where Do We Stand Today?
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“ DAPT after PCI remains essential, but balancing ischemic protection and bleeding risk is challenging. Over the past decade, trials have supported DAPT de-escalation—via dose reduction, drug withdrawal, or switching agents—to reduce bleeding without compromising ischemic outcomes in selected patients. Evidence for escalation is more limited. We wrote this review to summarize current data and ongoing studies. ”
Title: Dual Antiplatelet Therapy Escalation and De-escalation
Authors: Antonio Greco, Giacinto Di Leo, Simone Finocchiaro, Antonino Imbesi, Davide Capodanno
Read full article here.
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026